Cedazuridine; Decitabine Patent Expiration

Cedazuridine; Decitabine is Used for treating patients with CDA deficiency. It was first introduced by Otsuka Pharmaceutical Co Ltd in its drug Inqovi on Jul 7, 2020.


Cedazuridine; Decitabine Patents

Given below is the list of patents protecting Cedazuridine; Decitabine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Inqovi US11963971 Combination decitabine and cedazuridine solid oral dosage forms Feb 24, 2041 Otsuka
Inqovi US8268800 Certain compounds, compositions and methods Aug 22, 2030 Otsuka
Inqovi US8618075 Certain compounds, compositions and methods Oct 16, 2028 Otsuka
Inqovi US9567363 Certain compounds, compositions and methods Oct 16, 2028 Otsuka



Cedazuridine; Decitabine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List